References
- 1. CDC. Bigest Threats and Data 2019 AR Threats Report. 2019 [cited 2020]; Available from: https://www.cdc.gov/drugresistance/biggest-threats.html#cdiff.
- 2. Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011 Dec;155(12):839–47.10.7326/0003-4819-155-12-201112200-0000722184691
- 3. Nelson RL, Malakun R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;(9).10.1002/14651858.CD004610.pub421901692
- 4. Sartelli M, Di Bella S, McFarland L V, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8.10.1186/s13017-019-0228-3639402630858872
- 5. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013 Apr;108(4):478–98.10.1038/ajg.2013.423439232
- 6. Dumitru IM, Dumitru E, Cernat RC, Petcu AE, Ilie Șerban C, Rugină S. Clostridium difficile colitis – a serious current problem. BMC Infect Dis. 2013;13(1):O20.10.1186/1471-2334-13-S1-O20
- 7. Crawford T, Huesgen E, Danziger L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2012 Jun;69(11):933–43.10.2146/ajhp11037122610025
- 8. Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect. 2012;18:28–35.
- 9. Dumitru IM, Dumitru E, Rugina S, Tuta LA. Toxic Megacolon - A Three Case Presentation. Vol. 3, Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures). 2017. p. 39–44.10.1515/jccm-2017-0008576989029967870
- 10. Dumitru IM, Dumitru E, Alexandrescu L, Hangan A, Rugina S, Lilios G. Human Microbiome, Clostridium difficile and health. J Environ Prot Ecol. 2015;16(4):1598–602.
- 11. Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc. 2013 Aug;61(8):1394–8.10.1111/jgs.1237823869970
- 12. Dumitru IM, Dumitru E, Resul G, Curtali L, Paris S, Rugina S. Concomitant CMV and Clostridium difficile colitis in an immunocompetent patient treated with Ganciclovir and fecal transplantation. Vol. 23, Journal of gastrointestinal and liver diseases : JGLD. Romania; 2014. p. 221–2.10.15403/jgld-1286
- 13. Vigvári S, Nemes Z, Vincze Á, Solt J, Sipos D, Feiszt Z, et al. Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection. Orv Hetil. 2014;155(44):1758–62.10.1556/OH.2014.3002025344853
- 14. Khan MA, Sofi AA, Ahmad U, Alaradi O, Khan AR, Hammad T, et al. Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol. 2014 Sep;28(8):434–8.10.1155/2014/695029421023425014180
- 15. Institute Predictive Presonalised Medicine. Fecal Transplantation. [cited 2020]; Available from: https://www.ippmclinic.com/en/fecal-transplantation.
- 16. Wang J-W, Kuo C-H, Kuo F-C, Wang Y-K, Hsu W-H, Yu F-J, et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019 Mar;118 Suppl 1:S23–31.10.1016/j.jfma.2018.08.01130181015